Early-stage immunotherapy Gilboa Therapeutics is a preclinical-stage cancer immunotherapy company focused on SolidT T cell technology, representing an opportunity to engage in early discussions about research collaborations, joint development, or grant-funded programs with a biotech partner seeking pipeline acceleration.

SolidT platform potential The SolidT platform targets antibody-coated tumor cells with engineered T cells and claims efficacy in animal models with improved safety; sales opportunities exist in licensing, co-development, or sponsored research with larger biopharma seeking novel solid and hematologic cancer approaches.

Academic origin Technology originated in Tel Aviv University (Dr. Yaron Carmi’s lab), which can facilitate partnerships with academic spinouts or university-affiliated programs, enabling collaboration on translational studies, access to preclinical data, and potential government or foundation funding alignment.

Funding signals Current revenue is minimal, indicating reliance on non-dilutive funding, grants, or partner deals; sales opportunities could focus on upfront licensing fees, milestone-based payments, and strategic partnerships with cash-rich companies seeking early-access biology.

Tech and branding Presence on GoDaddy and public statements about proprietary SolidT technology offer a tangible entry point for outreach through digital marketing, investor relations, and targeted BD pitches highlighting a differentiated cell therapy platform with potential safety advantages.